TearLab Announces Changes To Its Board Of Directors
SAN DIEGO, Aug. 30, 2010 (GLOBE NEWSWIRE) -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced today the resignation of board member Thomas N. Davidson, 70, as per his planned retirement. The Company also announced that Brock J. Wright, MD, FRCPC has been appointed to its Board of Directors effective immediately.
Dr. Wright currently serves as Assistant Professor and Associate Dean, Clinical Affairs, Faculty of Medicine at the University of Manitoba and Senior Vice-President Clinical Services and Chief Medical Officer for the Winnipeg Regional Health Authority. The Winnipeg Regional Health Authority is responsible for all health services in Winnipeg, Manitoba with an operating budget of approximately $2 billion per annum.
Elias Vamvakas, TearLab's Chief Executive Officer, said, "We are fortunate to have Dr. Wright join our team. Brock brings a tremendous wealth of experience in health services delivery management and has a proven track record of success in operations management. His expertise in state-run healthcare, regulatory and reimbursement will be particularly invaluable to the success of the commercialization of the TearLab™ Osmolarity System in jurisdictions outside of the U.S.""On behalf of the Board and staff of TearLab, I would like to take this opportunity to thank Tom Davidson for his many contributions to the Company. He was instrumental in the founding of Occulogix. We are all grateful for Tom's continued guidance and support and wish him well in his retirement," added Mr. Vamvakas. About The TearLab™ Osmolarity System The TearLab™ Osmolarity System uses a novel lab-on-a-chip approach that requires less than 50 nL (nanoliters) of tear fluid in order to measure tear Osmolarity. The TearLab™ Osmolarity System eliminates the challenges that previously prevented point-of-care Osmolarity testing. The TearLab™ System can produce a sample-to-answer result in less than 30 seconds. About Dry Eye Disease DED is a common condition in which the eye does not produce enough tears to keep the surface of the eye sufficiently lubricated. It affects approximately 40 million people in the US and 100 million people worldwide. In its mild to moderate forms, it can impact vision and the ability to go about daily activities. In its more severe forms, DED can lead to permanent loss of vision.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV